

Chemical Engineering Journal

Braided Suture-Reinforced Fibrous Yarn Bundles as a Scaffold for Tendon Tissue Engineering in Extensor Digitorum Tendon Repair

--Manuscript Draft--

Manuscript Number:	CEJ-D-22-21954
Article Type:	Research Paper
Section/Category:	Novel Materials for Energy and Advanced Applications
Keywords:	Electrospinning; scaffold; yarn; tissue engineering; dynamic culture; basic fibroblast growth factor
Corresponding Author:	Jyh-Ping Chen Chang Gung University Taoyuan, Taiwan
First Author:	K.T. Shalumon
Order of Authors:	K.T. Shalumon Han-Tsung Liao Wei-Hao Lin Mini P.A. Jyh-Ping Chen
Abstract:	<p>In this study, we intend to develop an effective tendon tissue engineering scaffold that can provide mechanical stability and tendon regeneration ability. Using a novel electrospinning process, a biodegradable suture was continuously covered with aligned polycaprolactone fibers in core/sheath structure to produce a single yarn. The single yarn was braided together to fabricate a multi yarn (MY) scaffold, which can be surface modified with oxygen plasma and conjugated with heparin. The fibroblast growth factor 2 (FGF2) was bound to MY through bioaffinity between heparin and FGF2 to generate a functional scaffold (MY-FGF2) suitable for extensor digitorum tendon (EDT) repair. The physico-chemical properties of the scaffolds were characterized throughout the modification steps using microscopy, spectroscopy and mechanical testing. In vitro static culture using rabbit tendon-derived fibroblasts (rTFs) indicates combined effects of FGF2 and fiber alignment can enhance cell proliferation and extracellular matrix synthesis rates, as well as fasten tendon maturation. The cytoskeleton staining further endorses aligned morphology of fibers direct cell growth and collagen fiber deposition along the fiber axial direction, mimicking native tendon features. The dynamic culture in a bioreactor under uniaxial cyclic tensile loading authenticates 5% mechanical stimulation can further increase cell proliferation and tenogenic differentiation rates compared to static culture. After mechanical stimulation for 7 days in vitro, the MY-FGF2/rTFs construct was used for repair of EDT defects in rabbits. The retrieved MY-FGF2/rTFs sample 6-week post-implantation shows superior mechanical properties and tendon regeneration abilities over acellular MY-FGF2. Taken together, we demonstrate a combinatory approach with MY-FGF2 where chemical and physical cues provided by FGF2, fiber alignment and dynamic stimulation contribute to tendon regeneration with a specific focus on EDT repair.</p>

**CHANG GUNG UNIVERSITY**

September 16, 2022

Editor
Chemical Engineering Journal

Dear Editor:

We would like to submit a manuscript for consideration to be published in **Chemical Engineering Journal**.

Manuscript title: Braided Suture-Reinforced Fibrous Yarn Bundles as a Scaffold for Tendon Tissue Engineering in Extensor Digitorum Tendon Repair

Name of corresponding author: Jyh-Ping Chen

Name of all other authors: K.T. Shalumon, Han-Tsung Liao, Wei-Hao Lin, Mini P.A.

Type of Manuscript: Original paper

Significance: In this work, a novel electrospinning process was used to cover a biodegradable suture core with aligned polycaprolactone fiber sheath to produce a single yarn. Three single yarns were braided to fabricate a mechanical stable multi yarn (MY) scaffold for tendon tissue engineering. To introduce biochemical cues, MY was surfaced modified with heparin for binding with basic fibroblast growth factor (FGF2). In vitro studies using MY-FGF2 and rabbit tendon fibroblasts (rTFs) show enhanced cell proliferation and ECM synthesis rate as well as accelerated tendon maturation. Dynamic culture of MY-FGF2/rTFs under 5% cyclic tensile strains further increases cell proliferation and tenogenic differentiation rate. A dynamically cultured MY-FGF2/rTFs construct can repair EDT defect in rabbits with superior tendon regeneration abilities.

List of keywords: Electrospinning; scaffold; yarn; tissue engineering; dynamic culture; basic fibroblast growth factor

Authors' statements: The author has consulted the Guide for Authors in preparing the submitted manuscript and prepared the manuscript in compliance with the Ethics in Publishing Policy as described in the Guide for Authors. All authors have seen and approved the submission of the manuscript to the journal. The manuscript has not been published previously by any of the authors and/or is not under consideration for publication in another journal.

Names and addresses of recommend reviewers:

1. Dr. Helmut Thissen

Molecular Science

CSIRO

Australia

E-mail: helmut.thissen@csiro.au

2. Dr. Wenguo Cui

School of Medicine

Shanghai Jiao Tong University

China

wgcui80@hotmail.com

3. Dr. R. Jayakumar

Amrita Center for Nanosciences and Molecular Medicine

Amrita Institute of Medical Sciences and Research Centre

India

E-mail: rjayakumar@aims.amrita.edu

4. Dr. Tasuku Nakajima

Faculty of Advanced Life Science

Hokkaido University

Japan.

E-mail: tasuku@sci.hokudai.ac.jp

5. Dr. Cato T. Laurencin

Materials Science and Engineering

University of Connecticut

laurencin@uchc.edu

We hope that you will consider this manuscript for publication, and we are at your full disposal for any modifications suggested during the review process.

Sincerely yours,

Jyh-Ping Chen, PhD

Professor

Department of Chemical and Materials Engineering

Chang Gung University

Taoyuan, Taiwan, ROC

Names and addresses of recommend reviewers:

1. Dr. Helmut Thissen

Molecular Science

CSIRO

Australia

E-mail: helmut.thissen@csiro.au

2. Dr. Wenguo Cui

School of Medicine

Shanghai Jiao Tong University

China

wgcui80@hotmail.com

3. Dr. R. Jayakumar

Amrita Center for Nanosciences and Molecular Medicine

Amrita Institute of Medical Sciences and Research Centre

India

E-mail: rjayakumar@aims.amrita.edu

4. Dr. Tasuku Nakajima

Faculty of Advanced Life Science

Hokkaido University

Japan.

E-mail: tasuku@sci.hokudai.ac.jp

5. Dr. Cato T. Laurencin

Materials Science and Engineering


University of Connecticut

laurencin@uchc.edu

TOC Graphic

Braided Suture-reinforced Fibrous Yarn Bundles as a Scaffold for Tendon Tissue Engineering in Extensor Digitorum Tendon Repair

K.T. Shalumon, Han- Tsung Liao, Wei-Hao Lin, Mini P.A., Jyh-Ping Chen



rTFs seeded/mechanically stimulated MY-FGF2 scaffold is a promising candidate for tendon regeneration, with a specific focus on EDT repair

Highlights

1. A novel electrospinning process can cover a biodegradable suture core with aligned polycaprolactone fiber sheath.
2. Three yarns were braided to fabricate a mechanical stable multi yarn (MY) scaffold for tendon regeneration.
3. To introduce biochemical cues, MY was surfaced modified with heparin for binding with FGF2 (MY-FGF2).
4. In vitro study with MY-FGF2/rTFs shows enhanced cell proliferation, ECM synthesis and accelerated tendon maturation rate.
5. Dynamic culture of MY-FGF2/rTFs under 5% cyclic tensile strains further increases cell proliferation and tenogenic differentiation rate.
6. A dynamically cultured MY-FGF2/rTFs construct can repair EDT defect in rabbits with superior tendon regeneration abilities.

Braided Suture-Reinforced Fibrous Yarn Bundles as a Scaffold for Tendon Tissue Engineering in Extensor Digitorum Tendon Repair

K.T. Shalumon^{1,2†}, Han- Tsung Liao^{3†}, Wei-Hao Lin¹, Mini P.A.⁴, Jyh-Ping Chen^{1,3,5,6,7*}

¹Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan

²Department of Chemistry, Sacred Heart College, MG University, Kochi 682013, India

³Department of Plastic and Reconstructive Surgery and Craniofacial Research Center, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Kwei-San, Taoyuan 33305, Taiwan

⁴Department of Physics, St. Michael's College, Cherthala, University of Kerala, Kerala 688539, India

⁵Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Kwei-San, Taoyuan 33305, Taiwan

⁶Research Center for Food and Cosmetic Safety, College of Human Ecology, Chang Gung University of Science and Technology, Kwei-San, Taoyuan 33302, Taiwan

⁷Department of Materials Engineering, Ming Chi University of Technology, Tai-Shan, New Taipei City 24301, Taiwan

† K.T. Shalumon and Han-Tsung Liao contributed equally to this work

*Corresponding author

Tel: +886-3-2118800

E-mail: jpchen@mail.cgu.edu.tw

Keyword: Electrospinning; scaffold; yarn; tissue engineering; dynamic culture; basic fibroblast growth factor

32 **Abstract** In this study, we intend to develop an effective tendon tissue engineering scaffold
33 that can provide mechanical stability and tendon regeneration ability. Using a novel
34 electrospinning process, a biodegradable suture was continuously covered with aligned
35 polycaprolactone fibers in core/sheath structure to produce a single yarn. The single yarn was
36 braided together to fabricate a multi yarn (MY) scaffold, which can be surface modified with
37 oxygen plasma and conjugated with heparin. The fibroblast growth factor 2 (FGF2) was
38 bound to MY through bioaffinity between heparin and FGF2 to generate a functional scaffold
39 (MY-FGF2) suitable for extensor digitorum tendon (EDT) repair. The physico-chemical
40 properties of the scaffolds were characterized throughout the modification steps using
41 microscopy, spectroscopy and mechanical testing. In vitro static culture using rabbit tendon-
42 derived fibroblasts (rTFs) indicates combined effects of FGF2 and fiber alignment can
43 enhance cell proliferation and extracellular matrix synthesis rates, as well as fasten tendon
44 maturation. The cytoskeleton staining further endorses aligned morphology of fibers direct
45 cell growth and collagen fiber deposition along the fiber axial direction, mimicking native
46 tendon features. The dynamic culture in a bioreactor under uniaxial cyclic tensile loading
47 authenticates 5% mechanical stimulation can further increase cell proliferation and tenogenic
48 differentiation rates compared to static culture. After mechanical stimulation for 7 days in
49 vitro, the MY-FGF2/rTFs construct was used for repair of EDT defects in rabbits. The
50 retrieved MY-FGF2/rTFs sample 6-week post-implantation shows superior mechanical
51 properties and tendon regeneration abilities over acellular MY-FGF2. Taken together, we
52 demonstrate a combinatory approach with MY-FGF2 where chemical and physical cues
53 provided by FGF2, fiber alignment and dynamic stimulation contribute to tendon regeneration
54 with a specific focus on EDT repair.

55

56 **1. INTRODUCTION**

57 Tendons are fibrous soft connective tissues responsible for transmitting force and
58 connecting muscles and bones. Its main function is to stretch like a highly flexible elastic
59 spring that moves back and forth through elastic recovery. The mass of a tendon consists of
60 30% water, with the remaining dry mass consisting of 86% type I collagen, 1-5%
61 proteoglycan, 2% elastic fibers, 0.2% inorganic ingredients, and a small amount of other types
62 of collagen [1]. Considering the hierarchical structure of a tendon tissue, collagen fibrils
63 (~300 nm) in tendons are composed of collagen triple helix molecules of 20 to 150 nm
64 diameter. These collagen fibrils further form collagen fibers (20 μm), by arranging themselves

65 in a longitudinal manner and lead to a structure with high tensile strength. With parallel
66 arrangement, the collagen fibers in turn are bundled by tendon endocardium (endotenon) to
67 form fiber bundles (fascicles) with ~300 μm in size. These fiber bundles are also arranged
68 longitudinal to provide tensile strength of the tendon [2]. Therefore, with the complex
69 structure of tendon tissues, tendon repair has always been a problem for clinicians. In current
70 scenario, traditional clinical reconstruction and repair of tendon tissues follow two directions,
71 i.e. allografts or autografts. The allografts face problems like disease transmission, lack of
72 durability and functionality, insufficient supply, as well as storage methods during
73 transportation [3]. Considering this, auto-transplantation is widely used in a clinical setting,
74 where tendon autograft may provide the most satisfactory long-term results without immune
75 rejection. However, the possible necrotic behavior of the implant after transplantation could
76 result in inferior biomechanical stability and thereby leads to failure of the graft after tendon
77 reconstruction surgery.

78 Tissue engineering has been recognized as a promising strategy for tendon repair or
79 reconstruction [4]. Various studies have been performed to understand the relevance of
80 fibrillary microarchitecture and the functional characteristics of native tendon extracellular
81 matrix (ECM). One of the long-term needs in tendon tissue engineering is to recover the
82 damaged tissues with full regeneration of their biological functions. Therefore, a functional
83 tissue engineered tendon should have good biological activity as well as suitable
84 biomechanical properties. For this, cells seeded in a tissue engineering scaffold for tendon
85 regeneration should retain good proliferation ability and induce phenotype maintenance or
86 differentiate towards the tenogenic lineage during long-term culture in vitro [5]. In order to
87 achieve this goal, a three-dimensional (3D) scaffold for tendon tissue engineering should be
88 biodegradable, biocompatible, provide proper space for cell growth, and ultimately possess
89 proper mechanical or chemical stimulation capability [6]. Furthermore, as tendons are
90 regularly subjected to continuous action of tensile loading from muscle contraction, their
91 development and regeneration is closely related to tensile mechanical loading. To tissue
92 engineering a tendon tissue, mechanical stimulation during cell culture has been proved to
93 improve the biological outcomes and mechanical properties of the scaffold/cell construct [7].

94 Various scaffolds fabricated from different biomaterials have been suggested to
95 resemble the tendon architecture and to achieve the unique biomechanical properties of
96 tendons. The scaffold topography and morphology is crucial for successful regeneration of a
97 tendon. Specifically, fiber-fabricating techniques as well as textile processes have been

98 employed to engineer and generate fibrous constructs for tendon tissue development [8]. The
99 use of micrometer-scale yarn is one of the methods [9], where textile-based scaffolds could
100 uniquely combine size, shape, load-bearing and strength-retention abilities for tendon repair
101 [10, 11]. However, those textile scaffolds generated from microfiber yarns are different from
102 the inherent nanoscale organization of collagen fibrils in native tendon ECM. This could
103 result in reduced cellular activity and inferior regeneration outcomes [12-14]. Polymeric
104 fibers can be fabricated into different sizes and shapes to meet specific mechanical and
105 biological requirements as an ideal tissue engineering scaffold. Textile techniques like
106 knitting, weaving, braiding etc. can further process the fibers into a more complex 3D
107 structures. Also, the mechanical properties of the scaffolds can be easily modulated through
108 changes in parameters like fiber diameter, angle of braiding, bundle number and morphology
109 of bundles [15]. Although microfibers are good candidate for tendon scaffold/graft
110 development in terms of mechanical stability, their biological activities are not sufficient to
111 achieve effective regeneration. Some of the non-degradable synthetic materials used before
112 for this purpose, e.g. polyethylene terephthalate (PET), polytetrafluoroethylene (PTFE) and
113 polypropylene (PP), were only met with limited success due to this deficiency [16, 17]. From
114 this perspective, designing a fibrous scaffold from biodegradable polymers with relatively
115 small fiber diameter but with high mechanical strength would be preferred, as improved
116 biological activities were reported by using smaller fiber size [18]. Furthermore, electrospun
117 aligned fibers that have the anisotropic structure like collagen fibers in a tendon are more
118 advantageous when used for tendon tissue engineering, due to their ability to effectively
119 propagate mechanobiological cues in an *in vivo*-like manner [19, 20].

120 Apart from structural, topographical and mechanical mimicking of a native tendon by
121 a scaffold, the combination of biological components, such as growth factors and cell source,
122 with the developed scaffold should be also considered towards development of a tendon
123 construct [21]. Basic fibroblast growth factor (FGF2), growth and differentiation factor-5,
124 insulin-related growth factor-1, and platelet rich plasma are reported biochemical cues to
125 enhance the ECM production and tensile strength of treated tendons [22]. Considering cell
126 source, tendon-derived cells such as tendon-derived fibroblasts of autologous or allogenic
127 nature will be a suitable choice as a tendon tissue is composed of this cell type. However,
128 properly maintaining tenogenic phenotype in a 3D scaffold during *in vitro* cell culture still
129 represents a challenging task using this cell source. Other cell sources like bone marrow stem
130 cells and adipose-derived stem cells may be also considered, albeit a suitable niche must be

131 provided to achieve proper induction into the tenogenic lineage. Considering these facts, a
132 flexible fibrous scaffold, with good mechanical strength, tunable biodegradability and
133 biocompatibility, as well as incorporated with a suitable growth factor, for seeding tendon-
134 derived fibroblasts will be under high demand for the development of a functional tendon
135 tissue.

136 The present work deals with the combination of all the ideal factors for tendon tissue
137 development, especially the mechanical stability of the scaffold. A slow biodegradable
138 polymer polycaprolactone (PCL) was selected as the base material for the fabrication of sub-
139 micron scale aligned fibers. A commercial suture (Ethicon PDS II 2-0) was chosen as the
140 reinforcing core inside this fibrous layer for its higher mechanical strength. The aligned fiber
141 collected around the suture serve as a sheath to cover the suture in core/sheath structure. The
142 suture-embedded single yarn (SY) could be facilely grafted with heparin for binding FGF2
143 through bioaffinity interactions. Afterward, three SY were braided to fabricate a multi yarn
144 (MY) scaffold with higher mechanical strength. After comprehensive material
145 characterization, we will carry out in vitro static and dynamic cell culture by seeding rabbit
146 tendon-derived fibroblasts (rTFs) in MY or MY-FGF2 scaffold. A MY-FGF2/rTFs construct
147 after mechanical loading in vitro will be chosen to repair extensor digitorum tendon (EDT)
148 defects in rabbits.

149

150 **2. EXPERIMENTAL SECTION**

151 **2.1 Materials**


152 Polycaprolactone (PCL, molecular weight = 900 kDa), chloroform, methanol, N-
153 hydroxysuccinimide (NHS), heparin sodium salt, Dulbecco's modified Eagle's medium-high
154 glucose (DMEM), (2-(4-amidinophenyl)-6-indolecarbamidine (DAPI) for nuclear staining,
155 phalloidin-tetramethylrhodamine B isothiocyanate (phalloidin-TRITC) for F-actin staining,
156 bisBenzimide H 33258 for DNA quantification were purchased from Sigma-Aldrich. 1-(3-
157 Dimethylaminopropyl)-3-ethylcarbodiimide (EDC) was obtained from Acros. 2-(N-
158 Morpholino)ethanesulfonic acid (MES) and acetonitrile was procured from J.T.Baker. PEG-
159 diamine (molecular weight = 3500) was obtained from Jenkem Technology. HyClone fetal
160 bovine serum (FBS) and Live/Dead viability/cytotoxicity kit for mammalian cells was
161 acquired from Thermo Fisher Scientific. Basic human recombinant fibroblast growth factor
162 (FGF2) was acquired from ProSpec. The Ethicon PDS II (polydioxanone) 2-0 suture was
163 provided by Johnson & Johnson.

164 2.2 Preparation of scaffolds

165 2.2.1 Preparation of suture-reinforced single yarn by electrospinning

166 The spinning solution is 11%(w/v) PCL prepared in chloroform/methanol (7/3 volume
167 ratio). A custom-made electrospinning setup was used for to fabricate suture-embedded PCL
168 fibrous single yarn. Three 10-mL syringes (Terumo) were filled with the PCL solution and
169 placed in a multi syringe infusion pump (KDS 220, KD Scientific). Another 10-mL syringe
170 (Terumo) filled with PCL solution was fitted in a single syringe infusion pump (KDS100, KD
171 Scientific). The syringes in the multi syringe pump were separately connected to three equally
172 placed metallic blunt-edged needles (21 G) in a Teflon disk using silicone tubes, while the
173 syringe in the single syringe pump was directly connected to a metallic needle. Two power
174 supplies for electrospinning were used in the study, with needles from the multi syringe pump
175 connecting to a positive power supply and the needle from the single syringe pump
176 connecting to a negative power supply. Both syringe pumps were kept at ~45° angle towards
177 a metallic plate that is connected to a grounded AC motor. Six metallic rods (15 cm length,
178 0.8 cm diameter) were equally fixed to the peripheral of the metallic plate at 15° angle for
179 collecting the fibers. A paper cup containing disentwined biodegradable suture (Ethicon PDS
180 II 2-0) was fixed horizontal inside the inner metallic plate of the rotor. A small hole was made
181 at the center of the paper cup and the suture was kept protruded outside the cup, prior to
182 electrospinning. A rotating yarn collector was placed at the other end of the fiber collector to
183 collect a yarn on its rod. The spinning solution was delivered at 4 mL/h flow rate by both
184 syringe pumps at 20 kV, which produced both negatively-charged and positively-charged
185 fibers. The fibers were continuously deposited and twisted in clockwise direction by rotating
186 the metallic plate at 50 rpm to achieve an inter-twisting fibrous environment. The suture
187 protruding from the paper cup was further hooked to a sharp wooden stick and then slowly
188 extended towards the yarn collector. The distance between the metallic fiber collector and all
189 syringe needle tips were at an optimized value of 5 cm for best fiber coverage over the
190 continuously extending suture. The paper cup with the disentwined suture was designed to
191 release the twisting tension generated on the protruding end of the suture to the other end,
192 through free rotation inside the cup. A suture covered with slightly twisted fibers could be
193 pulled towards the rod in a yarn collector rotating at 2.5 rpm for collection of suture-
194 reinforced single yarn (SY) (0.4 mm diameter), using 70-cm long suture in a single run
195 **(Figure 1, Step 1).**

196



197

198 **Figure 1.** A schematic diagram showing the electrospinning process to obtain suture-
 199 reinforced single yarn (SY) covered with aligned PCL fibers, and braiding of three SY to
 200 obtain multi yarn (MY) scaffolds.

201

202 2.2.2 Braiding of suture-reinforced single yarn (SY) to get multi yarn (MY) scaffold

203 During this process, three SY were selected in equal length and kept together as a
 204 bundle. One end of the bundle was fixed on a clip and further braided to the other end to
 205 obtain a braided fibrous multi yarn (MY) scaffold with 0.1-cm knots (**Figure 1, Step 2**). The
 206 MY scaffold was cut into a suitable length and both ends were tied with Nylon 5-0 sutures to
 207 prevent un-winding of yarns.

208 2.2.3. FGF2-conjugated multi yarn (MY-FGF2) scaffold

209 The MY scaffold was modified in multiple steps for FGF2 conjugation (**Figure S1,**
 210 **Supplementary Materials**). The scaffold was first subject to plasma treatment in a DC-
 211 pulsed plasma system for surface activation of MY [23]. A customized bipolar electrode

212 device was used for the surface treatment. MY was cut into 1-cm length prior to the
213 experiment and treated with oxygen plasma generated from a SPIK 1000A oxygen plasma
214 generator at 600 V and 200 mTorr for 120 s to obtain plasma-treated MY (PMY). The PMY
215 was incubated in 0.5 M MES buffer (pH 7) containing 1 mg EDC and 1 mg NHS to activate
216 the carboxyl groups on PMY surface, followed by adding 3 nmol of PEG-diamine. The PEG
217 binding process was carried out for 24 h to obtain MY-NH₂. In order to conjugate heparin,
218 MY-NH₂ was further reacted with 1.2 nmol heparin in EDC/NHS solution prepared in MES
219 buffer for 24 h, similar to PEG-diamine conjugation. The heparin-bound scaffold (MY-H) was
220 washed and placed in an UV box (100 $\mu\text{J}/\text{cm}^2$) for 4 h on each side for sterilization. The
221 sterilized MY-H was immersed in sterilized FGF-2 solution prepared in phosphate buffered
222 saline (PBS) (2 $\mu\text{g}/\text{mL}$) for 24 h and washed with PBS and water repeatedly to obtain FGF2-
223 conugated MY (MY-FGF2) scaffolds.

224

225 **2.3 Characterization of scaffolds**

226 **2.3.1 Quantification of carboxyl group on PMY**

227 A dried PMY was weighed and immersed in 1 mL of 0.5 mM Toluidine Blue O (TBO)
228 at room temperature for 5 h, followed by washing with 0.01 M NaOH and drying in a vacuum
229 oven at 37 °C to complete dryness. The dried sample was taken out and treated with 2 mL
230 50%(v/v) glacial acetic acid for complete desorption of TBO. The solution absorbance was
231 measured using an UV/ VIS spectrometer at 633 nm. The concentration of carboxyl groups on
232 the surface of the scaffold was measured from a standard curve of TBO assuming 1:1 binding
233 ratio of carboxyl groups with TBO.

234 **2.3.2 Quantification of amine groups on MY-NH₂**

235 To quantify the amine group on MY-NH₂ surface, 300 μL of 0.25M o-
236 phthaldialdehyde (OPA) was mixed with 4% β -mercaptoethanol prepared in 0.1 M Na₂B₄O₇
237 (pH = 9.5), and made up to 75 mL using distilled water to obtain 1 mM OPA solution.
238 Another solution was prepared by mixing 500 μL of 0.06 M glycine with 500 μL of 0.5% β -
239 mercaptoethanol, and made up to 30 ml using distilled water to reach a final glycine
240 concentration of 1 mM. An OPA standard curve was made from 0.1 mM to 1 mM. A MY-
241 NH₂ (1-cm length) was put inside a glass bottle containing 1 mL of OPA solution. The bottle
242 was shaken for 10 min followed by collecting 50 μL of the supernatant. One mL of 0.1 M
243 Na₂B₄O₇ and 100 μL of glycine solution were mixed with the supernatant for 10 min. The
244 solution absorbance was determined with an UV/VIS spectrometer at 340 nm to estimate the

245 concentration of reacted OPA. The number of -NH₂ group on MY-NH₂ surface was estimated
246 by assuming 1:1 binding ratio between OPA and -NH₂.

247 **2.3.3 Quantification of heparin on MY-H**

248 After reacting heparin with MY-NH₂, the supernatant was collected and analyzed by
249 high performance liquid chromatography (HPLC) for unreacted heparin. A HPLC system was
250 used to determine the absorbance at 210 nm using KH₂PO₄/acetonitrile/methanol = 72/18/10
251 (v/v) as the mobile phase at a flow rate of 0.5 mL/min. An Eclipse XDB-C18 reverse phase
252 HPLC column (250 mm x 4.6 mm) was used.

253 **2.3.4 Quantification of FGF-2 grafting on MY-FGF2**

254 The quantitative estimation of surface grafted FGF2 on MY-FGF2 was achieved by
255 determining the FGF2 concentration in the washing solution with a commercial human bFGF
256 ELISA kit (RayBiotech ELH-bFGF). To visualize the distribution of surface-grafted FGF2,
257 MY-FGF2 was treated with anti-FGF2-FITC antibody (4 µg/mL) for 1 h and observed under
258 a confocal microscope (Leica TCS SP2), after washing in PBS.

259 **2.3.5 Morphology of scaffold by scanning electron microscopy**

260 The surface morphology of fibrous yarns after each surface attachment/grafting step
261 was observed under a scanning electron microscope (SEM, Hitachi S3000N). The sample was
262 fixed onto a carbon tape pasted on aluminum stub and sputter coated with gold for 60 s at 20
263 mA. The surface morphology, thickness of fiber deposition and fiber alignment were
264 observed at 15 kV and the respective images were compared with its physical structure.

265 **2.3.6 X-ray spectroscopy (EDS) and X-ray photoelectron spectroscopy (XPS)**

266 The surface elemental composition was analyzed using a scanning electron
267 microscope (SEM, JEOL JSM-7500F) equipped with energy-dispersive X-ray spectroscopy
268 (EDS, Bruker AXS-5030). Surface treated scaffolds were allowed to undergo elemental
269 detection to confirm successful surface modification. The surface chemical composition was
270 also verified through X-ray photoelectron spectroscopy (XPS). A Physical Electronics PHI
271 1600 ESCA photoelectron spectrometer having a spherical capacitor analyzer and a multi-
272 channel detector was used for the study. The binding energy from 0 to 1300 eV was recorded.

273 **2.3.7 Thermogravimetric analysis**

274 Thermal properties were evaluated by thermogravimetric analysis (TGA) (TGA 2050,
275 TA Instruments). The samples were heated in nitrogen environment at 10 °C/min heating rate
276 from 30 to 700 °C. The TGA thermograms were recorded as weight (%) vs temperature (°C).

277 The derivative thermogravimetric (DTG) curves are presented as derivative weight (%/°C) vs
278 temperature (°C).

279 **2.3.8 Mechanical properties**

280 The mechanical properties of MY and MY-FGF2 scaffolds were tested through tensile
281 mechanical testing. Both ends of a 1.5-cm long sample were fixed in a metallic grip holder to
282 get a gauge length of 1 cm. A tensile testing machine (Bose ElectroForce BioDynamic) was
283 used to measure the mechanical properties of MY and MY-FGF2 at 0.2%/s strain rate.

284

285 **2.4 In vitro studies**

286 **2.4.1 Isolation of rabbit tendon-derived fibroblasts (rTFs)**

287 The rabbit tendon-derived fibroblasts (rTFs) was isolated from New Zealand white
288 rabbits (8-10 weeks old and 3.0-4.0 kg), as reported earlier with slight modification [24]. All
289 procedures were approved by the Institutional Animal Care and Use Committee of Chang
290 Gung University. Rabbits were sedated using intra-muscular injection of ketamine (10
291 mg/kg) and xylazine (3 mg/kg). After sacrificing the animals, their flexor tendons were
292 dissected by cutting the tendon tissues 5-mm from the tendon-bone insertion and tendon-
293 muscle junction. The tendon sheath and paratenon were removed and the isolated tendon
294 tissues were weighed and minced into small pieces. Tissue samples were digested in
295 collagenase/dispace solution prepared in PBS at 37 °C for 1 h. The suspension was
296 centrifuged at 1,500 g for 15 min and the pellet was re-suspended in DMEM containing 20%
297 FBS, 1% penicillin-streptomycin and 3.7 g/L sodium bicarbonate. The suspension was
298 transferred to T75 flasks and incubated in a CO₂ incubator at 37 °C for two weeks for
299 migration of rTFs to the culture plate surface. The rTFs was detached through 0.05%
300 trypsin/EDTA treatment and sub-cultured in T-75 flasks with medium change every three
301 days.

302 **2.4.2 Static culture of rTFs in MY and MY-FGF2**

303 The MY or MY-FGF2 with 1-cm length were sterilized by UV light or 4 h at 100
304 μJ/cm² on each side and pre-wetted with cell culture medium prior to cell seeding. A 10-μL
305 cell suspension containing 1 × 10⁵ rTFs was seeded to each scaffold. After 4 h of cell seeding,
306 2 mL DMEM was added to immerse the sample and cell culture was carried out in a CO₂
307 incubator at 37 °C with medium change every three days.

308 **2.4.3 Morphology, viability and cytoskeletal arrangement of rTFs on MY and MY-FGF2**

309 After culture for different times, a cell-seeded scaffold was fixed in 2.5%
310 glutaraldehyde for 30 min and followed by PBS washing. A gradient alcohol washing was
311 given to remove water content from the sample, which is further vacuum dried. The
312 morphology of adhered cells was examined through SEM (Hitachi S-3000N). The viability of
313 rTFs in the scaffold was determined through Live/Dead assays [25]. At each time point, the
314 samples were stained with calcein AM/ethidium homodimer in a Live/Dead
315 viability/cytotoxicity kit. All samples were washed with PBS after staining and observed
316 under a confocal laser scanning microscope (Zeiss LSM 510 Meta) at excitation/emission
317 wavelength of 494 nm/517 nm for live cells, and excitation/emission wavelength of 528
318 nm/617 nm for dead cells. To observe cytoskeletal arrangement, the samples were fixed with
319 glutaraldehyde, followed by permeabilization in 0.1% Triton X-100 for 10 min at room
320 temperature. Thereafter, they were stained with red fluorescence-producing phalloidin-TRITC
321 (1 $\mu\text{g}/\text{mL}$) for 30 min, and blue fluorescence-producing DAPI (1 $\mu\text{g}/\text{mL}$) for 10 min. The
322 orientation of actin microfilaments in adhered rTFs was visualized through a confocal laser
323 scanning microscope (Zeiss LSM 510 Meta) at excitation/emission wavelength of 540
324 nm/545 nm for phalloidin-TRITC and excitation/emission wavelength of 358 nm/461 nm for
325 DAPI.

326 **2.4.4 Cell proliferation**

327 The cell seeded scaffold was removed from the culture plate and washed three times
328 with PBS at pre-determined time points. The samples were then immersed in 1 mL digestion
329 buffer (55 mM sodium citrate, 150 mM sodium chloride, 5 mM cysteine, 5 mM EDTA and
330 0.2 mg/ml papain) by shaking at 60 °C for 24 h. The solution was centrifuged at 20 °C for 5
331 min, and 10 μL of supernatant was mixed with 200 μL of 10 mg/ml bisBenzimide H 33258
332 solution. The fluorescence intensity was measured using an ELISA reader (Synergy HT,
333 BioTek) [26].

334 **2.4.5 Gene expression**

335 The gene expression of type I collagen (COL I), type III collagen (COL III), tenacin
336 C, biglycan and fibronectin were examined using standard protocols for RNA isolation and
337 cDNA synthesis.[27] The quantitative real-time polymerase chain reaction (qRT-PCR) was
338 performed using a SYBR[®] Green RT-PCR kit (SYBR Green I supermix) with a MiniOption
339 detection system (Bio-Rad CFD-3120). The glyceraldehyde 3-phosphate dehydrogenase
340 (GAPDH) was used as a housekeeping gene for internal control. The gene expression analysis
341 was carried out using the $2^{-\Delta\Delta C_t}$ relative quantification method and reported as relative

342 expression by normalizing the relative mRNA content for each gene with its respective value
343 on day 0. The primers used for the study are listed in **Table S1 (Supplementary Materials)**.

344 **2.4.6 Immunofluorescence staining**

345 For immunofluorescence (IF) staining of COL I and tenascin C, the samples were
346 rinsed with PBS and fixed with 4% paraformaldehyde in PBS for 30 min, followed by
347 washing with PBS/0.1% Tween 20 (PBST) for 3 times (15 min each). The sample was treated
348 with 1 mL of HyBlock 1-min Blocking Buffer and washed by PBST. The COL I (1:2000 in
349 PBST, mouse monoclonal anti-COL I, Abcam, USA) and tenascin C primary antibodies
350 (1:1000 in PBST, mouse monoclonal anti-tenascin-C, Abcam, USA) were separately reacted
351 with each sample for 24 h at 37 °C. The sample was further washed with PBST and incubated
352 with goat anti-mouse IgG-FITC secondary antibody (1:200) (Jacksons Laboratories) for 2 h.
353 The incubation was terminated by PBST washing and further stained with DAPI (1 µg/mL)
354 for 15 min for nuclear stain. The samples were examined under a Leica TCS SP2 laser
355 scanning microscope (Wetzlar, Germany) and imaged using excitation/emission wavelength
356 of 490/519 nm for FITC and 358/461 nm for DAPI, respectively. A semi-quantitative analysis
357 of COL I and tenascin C was performed through the area percentage of the green fluorescence
358 signal corresponding to COL I or tenascin C in each image using the PAX-it!TM image
359 analysis software.,.

360 **2.4.7 In vitro dynamic cell culture**

361 For dynamic cell culture, the MY-FGF2 scaffold was selected and followed the same
362 sterilization and cell seeding procedures as described before for static cell culture. A 1.5-cm
363 length MY-FGF2 scaffold was fixed horizontally from both ends to clamps provided in a
364 bioreactor (BioDynamic 5100 single specimen mechanical stimulation bioreactor, TA
365 Instruments), leaving 1-cm length for seeding 1×10^5 rTFs [28]. After 4 h, the bioreactor was
366 filled with 175 mL of cell culture medium for cyclic tensile loading of the MY-FGF2/rTFs
367 construct in a CO₂ incubator at 37 °C and 5% CO₂. The construct was mechanically
368 stimulated 3 h per day at 0.5 Hz frequency, and with 0, 3 or 5% strain. After dynamic culture
369 for 7 days, the sample was removed from the bioreactor and subject to analysis following the
370 same experimental methods and analytical procedures as described above for static culture.

371

372 **2.5 In vivo studies**

373 The regeneration efficiency of the mechanical stimulated MY-FGF2/rTFs construct
374 was tested in extensor digitorum tendon (EDT) defect model in rabbits as per the animal

375 ethics protocols approved by the Institutional Animal Care and Use Committee of Chang
376 Gung University. For rabbit implantation studies, eight 6-8 month old New Zealand white
377 rabbits were selected and divided into two groups, viz., cellular and acellular groups. A 1.5-
378 cm MY-FGF2 scaffold was dynamically cultured with 1×10^5 rTFs at 5% strain for 7 days as
379 in dynamic cell culture and used as the cellular group. A 1.5 cm MY-FGF2 scaffold treated in
380 the same way in the bioreactor was used as the acellular group. The rabbits were anesthetized
381 by intramuscularly injecting 1:1 combination of Zoletil 50 and Rompun. Continued inhalation
382 of isoflurane was used to maintain the rabbit under anesthetic condition throughout the
383 experiment. The rabbit's legs were shaved, the muscles were opened and the EDT was
384 exposed. The tendon defect was created by removing 1-cm length ETD from both legs of the
385 animal. A cellular sample was implanted to the animal's left leg while an acellular sample
386 was implanted to its right leg, by suturing both ends of the scaffold separately to the proximal
387 and distal ends of the native tendon. The surgical sites were closed with nylon sutures and
388 cefozolin sodium was applied to the animal as a prophylactic antibiotic. The wound was
389 dressed with biomycin ointment to prevent infection. All animals were euthanized 6-week
390 post-implantation and the implant site was exposed using a scalpel. The sample was retrieved
391 by cutting at both ends of the native tendon and soaked in 10% formaldehyde for histological
392 analysis and in PBS for biomechanical tests. For histological analysis, paraffin-embedded
393 samples were sectioned for hematoxylin and eosin (H&E) staining, Masson's trichrome
394 staining, and immunohistochemical (IHC) staining of COL I, Col III and tenascin C. For
395 biomechanical tests, samples from acellular and cellular groups as well as native rabbit ETD
396 were subject to tensile mechanical testing (Bose ElectroForce BioDynamic) at 0.2%/s strain
397 rate.

398

399 **2.6 Statistical analysis**

400 The data are presented as mean \pm standard deviation. The one-way analysis of
401 variance (ANOVA) with the least significant difference (LSD) test was used for statistical
402 analysis. A p value less than 0.05 is considered statistically significant.

403


404 **3. RESULTS AND DISCUSSION**

405 **3.1 Fabrication and characterization of scaffolds**

406 The suture-reinforced single yarn (SY) was prepared as shown in **Figure 1**. The whole
407 set up has been optimized to uniformly and fully cover a 2-0 commercial suture with aligned

408 PCL fibers as a sheath. Using three needles connected to a positive power supply for
409 electrospinning, continuously deposition of PCL fibers on the surface of an extending suture
410 in possible. For continuous fiber collection, another needle connected to a negative power
411 supply was placed vertically from other needles, for collecting electrospun PCL fibers with
412 from electrostatic force generated from opposite surface charge. The combined use of both
413 positive and negative power sources hence can drive most of the fiber stream to the center of
414 the collection drum. The twisting of collected fibers on top of the extending suture can enable
415 efficient wrapping to entrap the suture within a single yarn. High-strength surgical sutures
416 with 300- μm diameter were selected here for the reinforcement of tendon scaffolds. Though
417 the suture inside the paper cup was revolving during drum rotation, the disentwined nature of
418 the suture resulted in free rotation of the suture terminal inside the cup, releasing the strain
419 experienced during electrospinning. The length provided by a single surgical suture was 70
420 cm, and its disentwined nature could be properly maintained throughout the process without
421 strain development for getting a single yarn (SY). The SY could be facilely collected with a
422 rotating rod fitted in a yarn collector. The rotation speed of the collection drum, flow rate of
423 the solution, and voltage for electrospinning has been optimized beforehand to obtain uniform
424 fiber deposition. Compared to non-woven and aligned fibrous structure fabrication, some
425 reports are available on yarn fabrication through electrospinning, whereas a dynamic liquid
426 support system was reported for continuous electrospun yarn fabrication [29]. A more similar
427 method of yarn fabrication was later reported as direct electrospinning [30]. However,
428 combination of a biodegradable suture and fibrous structure is developed here for the first
429 time to achieve higher mechanical stability, which is much relevant for tendon scaffold
430 fabrication.

431 The morphology of SY and braided MY scaffold examined under SEM reveals
432 uniform fiber deposition on suture surface (**Figure 2A and B**). A suture-embedded SY could
433 be prepared with 0.5 mm diameter, while braiding of three SY produces a bundled MY
434 scaffold of 1.25 mm diameter. The fibrous layer on the surface of SY and MY shown from the
435 SEM images reveals somewhat aligned fiber morphology by collecting with a rotating fiber
436 collector (**Figure 2C and D**).



437

438 **Figure 2.** The scanning electron microscopy images of suture-reinforced single yarn (SY)
 439 covered with PCL fibers (A and C), and multi yarn (MY) scaffolds from braiding of three SY
 440 (B and D).

441

442 As plasma treatment was used to generate carboxyl groups on MY surface to facilitate
 443 grafting of PEG-diamine, the optimum treatment duration to achieve maximum surface-
 444 grafted carboxyl groups must be studied. For this purpose, plasma treatment was carried out
 445 for different periods and the amount of carboxyl groups on the surface of PMY was measured
 446 using the TBO assay method (**Figure S2, Supplementary Materials**). The untreated sample
 447 showed background carboxyl groups at 0.12 ± 0.01 nmole/mg. The 60-s and 90-s plasma-
 448 treated samples displayed 0.51 ± 0.01 nmole/mg and 0.52 ± 0.03 nmole/mg contents, with no
 449 significant difference. When treated for 120 s, the content increased to 0.61 ± 0.01 nmole/mg
 450 and the value is significantly higher than those at 60 and 90 s. However, further increase of
 451 treatment time to 180 s resulted in similar $-\text{COOH}$ concentration with that observed for 120 s.
 452 Taken together, we chose 120 s as the optimum plasma treatment time to prepare PMY.


453 When PEG-diamine reacted with PMY in the presence of EDC/NHS, the carboxyl
 454 groups on PMY surface was activated, which can form amide bonds with the primary amine
 455 groups in PEG-diamine to yield MY-NH₂. To conjugate just one amine group in PEG-
 456 diamine to PMY while leaving the other amine group available for further reaction, we used a
 457 PEG-diamine concentration providing a 5 to 1 ratio of $-\text{NH}_2$ to $-\text{COOH}$ during the reaction.
 458 This process produced MY-NH₂ with 0.461 ± 0.018 (nmole/mg) free amine groups from the
 459 OPA assay. During the next heparin conjugation step, the EDC/NHS caused the activation of

460 carboxyl groups in heparin and formed amide bonds with free amine groups in MY-NH₂. The
461 dose of heparin used (~1.2 nmole) was controlled at 2.5 times that of free amine groups in
462 MY-NH₂ to obtain heparin-conjugated MY (MY-H). The heparin concentration on MY-H
463 surface was 0.585 ± 0.025 (nmole/mg) from unreacted heparin in the supernatant after
464 reaction. The scaffold surface during the surface modification steps are characterized by SEM
465 and included in **Figure S3 (Supplementary Materials)** for PMY, MY-NH₂ and MY-H. The
466 surface morphology of the yarns is found to be un-altered irrespective of successive surface
467 modification. The fiber topography was maintained and thus the yarn bundles maintained its
468 physical stability. It is also important to note that the inter- and intra-yarns spaces are highly
469 visible and thus it would be of great potential in terms of tissue engineering aspects.

470 The EDS spectrum and the elemental composition of MY, PMY, MY-NH₂ and MY-H
471 is shown in **Figure S4 (Supplementary Materials)**. Only C and O elements were detected on
472 MY surface as expected. After plasma treatment, the atomic percentage of O increased from
473 11.97% (MY) to 13.28% (PMY). It is inferred that oxygen plasma modification will increase
474 the carboxyl groups on the surface of the fibrous yarn scaffold, leading to increased oxygen
475 content. The successful introduction of amine groups was confirmed from the presence of
476 abundant nitrogen elements in the EDS spectrum of MY-NH₂ with 15.48% atomic
477 percentage. Finally, it could be clearly observed that after heparin conjugation, sulfur and
478 sodium start to show in the EDS spectrum of MY-H, with 0.11% and 0.04% atomic
479 percentages, respectively. Since heparin is a highly sulfated glycosaminoglycan and heparin
480 sodium salt was used here, we confirm successful surface conjugation of heparin to the
481 scaffold, which could be used for FGF2 binding.

482 X-ray photoelectron spectroscopy (XPS) is the energy analysis of surface generated
483 photoelectrons by x-ray irradiation. This photoelectron spectrum displays the characteristic
484 peaks for all elements except H and He, which can be used to identify the surface elements
485 qualitatively and quantitatively. Even minor shifts in peak positions implies the chemical
486 binding state of elements on the surface and thus the technique was used to examine the
487 chemical composition of the elements on the surface of the scaffolds. **Figure 3A** is the ESCA
488 analysis of MY, PMY, MY-NH₂ and MY-H, where C (286 eV) and O (534 eV) are the
489 common elements observed in all samples. Nitrogen in MY-H exhibited a peak at 401 eV
490 with an additional peak at 495 eV. It can be seen that the signal intensity of oxygen in PSY is
491 higher than that in MY after oxygen plasma treatment. The atomic percentage data justifies
492 the phenomenon where carbon percentage in PSY reduces to 73.44% from 83.53% in MY,

493 while oxygen content increases to 26.56% in PMY from 16.47% in MY. It is speculated that
 494 oxygen plasma modification increased the content of carboxyl groups on the surface of PMY
 495 and lead to an increase in oxygen content percentage. When PMY was further surface
 496 modified with amines, the nitrogen binding peak appeared on MY-NH₂ surface with a
 497 nitrogen atomic percentage of 1.77%, which does not appear in PMY. This infers to the
 498 successful amine binding in MY-NH₂. After heparin modification on MY-NH₂, the resultant
 499 MY-H sample displayed both the peaks of sulfur and sodium, evident from the atomic
 500 percentage values of 1.39% for Na and 1.05% for S. The nitrogen atomic percentage in MY-H
 501 is 1.27% and lower than that of MY-NH₂, due to the surface coverage of heparin over PEG-
 502 diamine, as has been reported previously [31].



503
 504 **Figure 3.** The XPS survey scan spectra (A), and the XPS C1s spectra (B) of MY, PMY, MY-
 505 NH₂ and MY-H.

506 The fractions of various carbon functional groups were further calculated from high-
 507 resolution XPS C1s spectra (**Figure 3B**), and the corresponding values are reported in **Table**
 508 **1**. The four peaks at 284.6, 286.2, 288.7 and 285.5 eV correspond to the C–H, C–O, and
 509 O=C–O and NH–C=O bonds in the PCL chain [32]. It is observed that the C-H content in MY
 510 decreased after oxygen plasma treatment with concomitant increase of C–O and O–C=O
 511 contents in PMY (**Table 1**). From the respective C1s spectra of MY-NH₂, the formation of
 512 amide bonds resulted in the decrease of O–C=O content from 16.47% in PMY to 13.92% in
 513 MY-NH₂ (**Table 1**). A NH–C=O peak appears in MY-NH₂ at 11.97%, confirming amide
 514 bond formation during introduction of –NH₂ groups using PEG-diamine. After heparin
 515 conjugation, the O–C=O content further reduced to 7.79% and the NH–C=O content
 516 increased to 13.24% in MY-H, confirming amide bond formation between heparin and amines
 517 groups in MY-NH₂. Taken together, the surface chemistry during the successive modification
 518 steps of MY to MY-H could be confirmed.

519

520 **Table 1.** Fraction of carbon functional groups from high resolution C1s XPS peaks.

Sample	C–H ~284.6 eV (%)	C–O ~286.2 eV (%)	O–C=O ~288.7 eV (%)	NH–C=O ~285.5 eV (%)
MY	74.29	13.56	12.15	0.00
PMY	67.20	16.32	16.47	0.00
MY-NH ₂	52.16	21.95	13.92	11.97
MY-H	61.41	17.55	7.79	13.24

521

522 Thermogravimetric analysis (TGA) is used to understand the effect of temperature,
 523 rate of decomposition and thermal stability of different polymeric materials when heated. It
 524 was used to analyze the thermal properties of MY and MY-H, from which components in the
 525 yarn bundles, i.e. sutures, PCL and heparin, could be confirmed. From TGA (**Figure S5A**,
 526 **Supplementary Materials**) and derivative thermogravimetric (DTG) curves (**Figure S5B**,
 527 **Supplementary Materials**), suture and PCL showed similar single stage decomposition
 528 pattern with onset thermal decomposition temperatures of 295 °C and 401 °C, respectively.
 529 Quantitative decomposition was found for suture and PCL at 500 °C, due to their synthetic
 530 polymer nature. The onset decomposition of MY was slightly higher than suture but
 531 significantly lower than PCL, confirming the combined effect from both suture and PCL. The
 532 steep decomposition of MY follows the same trend as suture until losing 80% weight,
 533 followed by a second-stage milder weight loss till 404 °C and finally attained 100%
 534 decomposition. The two-stage thermal decomposition pattern shown by MY leads to two

535 decomposition peak temperatures that could be assigned to suture and PCL, as observed from
536 the DTG curve. Being a mixture of sulfated polymers of carbohydrates sugar molecule,
537 heparin doesn't follow the decomposition characteristics of other synthetic polymers (suture
538 and PCL) in MY-H, and hence there was no sharp onset of decomposition. Heparin
539 disintegrated in a straight temperature proportion and retained 32% residual weight even after
540 700°C. Interestingly, MY-H showed mix properties of PCL, suture and heparin in its
541 decomposition pattern. The onset decomposition was identical to MY till 315 °C, followed
542 by a minor second-stage decomposition with a doublet peak temperature at 324 °C. Even after
543 700 °C, 7% residual weight of MY-H remains, which is not found for suture, PCL and MY.
544 Based on the results, it is inferred that heparin has been successfully grafted to the surface of
545 MY-H scaffold.

546 Successful binding FGF2 to MY-H was confirmed from confocal microscopy
547 observation. The control sample MY-H did not show any fluorescence signal due to the
548 absence of FGF2 while MY-FGF2 displays sporadic green fluorescence signals from binding
549 of FITC-labelled anti-FGF2 antibody to FGF2 on MY-FGF2 surface (**Figure S6A,**
550 **Supplementary Materials**). The distribution of FGF2 within a MY-FGF2 scaffold is also
551 evident by the comparing the SEM and confocal microscopy images (**Figure S6B,**
552 **Supplementary Materials**). From ELISA quantification of unbound FGF2 after reacting one
553 MY-H scaffold with 2 µg FGF-2, the amount of FGF2 bound to MY-H was almost
554 quantitative at 1.98 ± 0.01 µg per MY-FGF2 scaffold. Undoubtedly, the high binding
555 efficiency is due to the strong bioaffinity between heparin and FGF-2, where a dissociation
556 constant as low as 109 nM was reported [33]. Apart from protein binding, heparin can also
557 protect FGF-2 from proteolysis from in vitro and in vivo studies [34]. Furthermore, heparin
558 also modulates the mitogenic activity of FGF2 by inducing the dimerization of the FGF-R2
559 receptor [35]. Therefore, a 3D scaffold containing immobilized heparin could be employed
560 for the long-term anchoring of bioactive FGF2 to mediate cellular response of rTFs for tendon
561 tissue engineering.




562 As mechanical property is an important consideration of a tendon tissue engineering
563 scaffold, we used tensile mechanical testing to characterize MY and MY-FGF2 to elucidate
564 the effects of successive modification steps on their mechanical properties. The force-
565 displacement curves were used to calculate the stiffness, toughness, ultimate force and
566 ultimate displacement of MY and MY-FGF2 (**Figure S7, Supplementary Materials**). No
567 significance changes of mechanical properties was found between them, implies surface

568 plasma modification, chemical grafting of PEG-diamine and heparin, and physical binding of
569 FGF2 did not affect the mechanical stability of the suture-embedded scaffolds. The ultimate
570 displacement of ~1.7 mm occurred at the ultimate force in both MY and MY-FGF2 is
571 considered to be more suitable for resisting high tensile forces with limited elongation, as
572 reported for tendon mechanics [36]. The maximum strain calculated from the ultimate
573 displacement is 17%, which has been set as the strain limit during cyclic mechanical loading
574 of MY-FGF2 during dynamic cell culture.

575


576 **3.2 In vitro studies: static culture**

577 Using scanning electron microscope (SEM) to observe rTFs grown in MY and MY-
578 FGF2, **Figure 4A** reveals the cell morphology on day 0, 7, 14 and 21. Both scaffolds exhibit
579 similar cell adhesion pattern without significant differences. The cell density on day 0 and 7
580 were moderate in both scaffolds, but showed an interpenetrated cellular growth network on
581 day 14 and 21, where cells in MY-FGF2 appears to be more spreading. Cells in MY-FGF2 at
582 day 21 also displayed complete surface coverage compared to MY at the same time point. The
583 cells also show oriented growth pattern in the direction of fibers. The viability of rTFs in both
584 scaffolds were analyzed through the Live/Dead staining at different time points, with the
585 green fluorescence representing live cells and the red fluorescence referring to possible dead
586 cells (**Figure 4B**). Interestingly, both samples exhibited green fluorescence at all time points
587 irrespective of scaffolds. Relatively negligible amount of red stains appeared in the merged
588 images, underlining the biocompatibility of both scaffolds. As observed from SEM images,
589 the density of live cells was moderate on day 0 and 7. The cells appeared as intermittent green
590 spots on day 0 and turned out to be a well-oriented cell layer at later stages of cell growth.
591 The cell layering was more thick and defined for MY-FGF2 in comparison with MY, possibly
592 due to presence of FGF2. In order to validate the advantageous MY-FGF2 towards substrate-
593 specific cell growth, DAPI/phalloidin staining as used to observe cytoskeleton by labelling F-
594 actin in red with phalloidin-TRITC and cell nuclei in blue with DAPI (**Figure 4C**). Consistent
595 with previous SEM observations, time-dependent increase of cellular density is evident and
596 reaching the maximum at day 21, but more cells was found in MY-FGF2. The actin filaments
597 are found oriented along the fiber long-axis in the scaffolds, which may help the rTFs-seeded
598 scaffold to enhance its tensile properties. The DAPI-stained nuclei of MY-FGF2 also charted
599 an axial pattern of adhesion, confirming the successful growth and proliferation of rTFs
600 towards tendon regeneration.



602 **Figure 4.** The microscopy characterization of the rTFs after cultured in MY and MY-FGF2 for
 603 0, 7, 14 and 21 days through scanning electron microscopy (A, bar = 100 μ m), and confocal
 604 microscopy after Live/Dead (B, bar = 300 μ m) and cytoskeletal (C, bar = 75 μ m) staining.
 605

606 The proliferation of rTFs in MY and MY-FGF2 were assessed quantitatively and
 607 represented as DNA contents on day 0, 7, 14 and 21 in **Figure 5A**. Supporting previous
 608 microscopy observation shown in **Figure 4A**, the MY-FGF2 dominated the rate of cell
 609 proliferation over MY. For both scaffolds, the cell number increased rapidly with time. There
 610 is no significant difference in cell number on day 0, indicating similar cell attachment rate.
 611 Nonetheless, there is significant difference in DNA contents on day 7, 14, and 21. This
 612 underlines that FGF2 in MY-FGF2 may accelerate cell proliferation, as this growth factor is a
 613 well-recognized cell signaling molecule for neo-tendon tissue development during tendon
 614 healing [37]. This is also supported from the finding that FGF2 can promote cell mitosis and
 615 proliferation [38]. Considering the uniform distribution of FGF2 in MY-FGF2 as revealed in
 616 **Figure S6**, the DNA quantification results are affirmative of the bioactivity of FGF2 could be
 617 preserved by immobilization to MY-FGF2 scaffold though anchoring to heparin by
 618 bioaffinity binding. It should be noted that the cellular response elicited by FGF2 is
 619 irrespective to its free or immobilized form. The release of FGF2 from MY-FGF2 has been
 620 followed for 21 days in PBS during this study. However, no FGF2 could be detected in the
 621 release medium by ELISA due to the strong binding between FGF2 and heparin.



622

623 **Figure 5.** (A) The proliferation for rTFs in MY and MY-FGF2 by measuring the DNA
624 contents per scaffold. (B-F) The gene expression analyses of type I collagen (COL I), tenascin
625 C (C), type III collagen (COL III), biglycan (E), and fibronectin (F) by qRT-PCR.
626

627 A critical evidence of rTFs differentiation in presence of FGF-2 is the identification of
628 relevant tenogenic marker genes during in vitro cell culture. During differentiation, rTFs will
629 undergo different transition stages with regulated expression of various marker genes. The
630 relative gene expression of COL I, COL III, fibronectin, biglycan and tenascin C were
631 determining using GAPDH as a housekeeping gene, and normalized with its respective value
632 on day 0 (**Figure 5B-F**). COL I is the major protein in the ECM tendon tissue, where fibrillar
633 arrangement of triple-helical COL I molecules successively organized into tensile-resistant
634 fibrils, fibers and fiber bundles, and provide major resistance to mechanical forces. It is
635 deemed a late-stage gene marker for tendon repair with increased secretion throughout the
636 whole tendon repair [39]. During 21-day culture period in MY, rTFs show increased gene
637 expression of COL I with time. However, the relative value never exceed one by reaching its
638 initial value on day 0, indicating rTFs could partially recover their lost phenotype when
639 cultured in MY, possible originating from the biophysical cues provided by aligned fibers in
640 the scaffold without FGF2 [40]. Although the COL I gene expression in MY-FGF2 shows
641 similar time-dependent increase as MY, significantly enhancement of mRNA levels over
642 those in MY was found at all time points, suggesting that FGF2 on fiber surface can elicit
643 biochemical cues to affect rTFs. This is consistent with the report that FGF2 can act on the
644 cell surface receptor by phosphorylated it for activating several downstream intracellular
645 secondary messenger molecules, and result in upregulated expression of this tenogenic marker
646 [41].

647 The COL III is the second most abundant type of collagens in tendon ECM, and found
648 in the endotenon and epitenon regions of normal tendons. When the tendon remodels and
649 develops during healing, COL III will be gradually replaced by aligned and long COL I fibrils.
650 It is an early-stage gene marker during tendon healing [42]. A different gene expression
651 pattern was thus observed for COL III from COL I, with decreased gene expression level with
652 time. Both MY and MY-FGF2 showed early expression of COL III on day 7 with relative
653 gene expression level above 1, endorsing aligned fibrous structural arrangement in the
654 scaffold contribute to expression of this early marker. On day 7 and 14, MY-FGF2 shows a
655 significantly higher level of COL III expression compared to MY, which was not found on
656 day 21. Since COL III is produced during the collagen maturation process, MY-FGF2 may be



657 suggested to provide a higher collagen maturation rate, which is beneficial for tendon
658 reconstruction. This is supported from insignificant COL III gene expression level difference
659 between both scaffolds on day 21 when approaching tendon maturation.

660 Like COL III, fibronectin is also an early-stage tendon marker gene with maximal
661 synthesis during cell proliferation, and declined synthesis during cell maturation by affecting
662 early cell attachment and survival [43]. It is a well-known marker for active connective tissue
663 repair and the down-regulation of fibronectin gene expression on day 21 is consistent with its
664 known gene expression pattern where fibronectin synthesis is less as rTFs matured and
665 accumulated collagens [44]. Therefore, significant differences was only observed for this gene
666 on day 14 between MY and MY-FGF2. The MY does not show significant change of
667 fibronectin gene expression level with time. In contrast, the MY-FGF2 shows significant
668 increase of mRNA level early from day 7 to day 14, followed by drastic down-regulation of
669 fibronectin gene expression, indicating FGF2 can promote tendon maturation.

670 The biglycan is considered as a late maker gene by regulating the action of many
671 growth factors throughout tendon healing, which also regulate the arrangement and diameter
672 of collagen fibrils in the ECM of healed tendon tissues [45]. The gene expression level of
673 biglycan increase slowly with time for MY with significance found only between day 7 and
674 day 21. Nonetheless, MY-FGF2 provides pronounced upregulated biglycan gene expression
675 throughout the culture period and significantly higher expression level was found for MY-
676 FGF2 over MY on day 14 and 21. This again highlights the benefit using the FGF2-loaded
677 MY-FGF2 for rTFs culture in neo-tendon tissue development in vitro. The tenascin C is a
678 unique protein in tendon tissue, which promotes regeneration and restoration of tendons.
679 Hence, gene expression of this protein should be upregulated throughout the growth and
680 maturation phase of tendon tissue. The MY shows increased gene expression of tenascin C
681 from day 14 to day 21. In contrast, continuous gene expression increase for MY-FGF2 is
682 evident with much higher level of mRNA increase from day 7 to day 21. The MY-FGF2
683 scaffold also significantly upregulated tenascin C gene expression on day 14 and 21 compared
684 with MY. Overall, FGF2-mediated gene expression pattern change could be clearly
685 demonstrated when rTFs were cultured in MY-FGF2, with upregulated expression of all
686 tenogenic marker genes. This implicates the preference use of MY-FGF2 for culture of rTFs
687 in vitro, to provide better maintenance of the tenogenic phenotype.

688 To complement the gene expression levels determined by qRT-PCR, the synthesis of
689 tendon marker proteins COL I and tenascin C were studied from immunofluorescence (IF)

690 staining (**Figure 6**). From confocal microscopy observation, the green fluorescence signal is
691 assigned to protein molecules after binding with the FITC-labelled antibody while blue spots
692 are the cell nuclei. The presence of COL I and tenascin C in MY and MY-FGF2 were
693 minimal on day 0, while a moderate staining intensity was observed for both scaffolds on day
694 7, irrespective of protein types. The proteins start showing increased deposition in the scaffold
695 after day 14, and reaching a much higher protein density on day 21 for both samples.
696 Interestingly, the secreted protein shows orientation possibly following the direction of
697 aligned fibers on day 7 and 14, which has been also found for cytoskeleton expression in
698 **Figure 4C**. The aligned pattern was not noticeable on day 0 due to minimum protein
699 deposition, while on day 21 it may be too thick for clear visualization. Overall, the IF-staining
700 images supports a higher rate of COL I and tenascin C synthesis by rTFs in MY-FGF2. A
701 semi-quantitative evaluation of COL I and tenascin C synthesis was performed by using an
702 image analysis software [46]. The quantified COL I area percentage in IF images at day 0 was
703 6.9% and 11.0% for MY and MY-FGF2, respectively. An increase in protein deposition rate
704 was observed at later stages, with concomitant increase of stained area percentage to 26.5%
705 (day 7), 38.8% (day 14) and 67.7% (day 21) for MY, and 40.3% (day 7), 66.4% (day 14) and
706 91.1% (day 21) for MY-FGF2. In a same way, the fluorescence stained areas of tenascin C
707 on day 0, 7, 14 and 21 are 9.0%, 29.6%, 43.7% and 66.7%, respectively, for MY. The values
708 are 14.7%, 43.2%, 60.3% and 94.0% for MY-FGF2. In both cases, MY-FGF2 had higher
709 protein deposition rate compared to MY at each time point. It is also noticeable that the
710 difference in protein deposition rate between MY and MY-FGF2 increases with time.
711 Considering COL I, the difference in protein quantification between MY-FGF2 and MY on
712 day 0 is 4.1%, while it is 23.4% on day 21. Similarly for tenascin C, it is 5.7% and 27.3% on
713 day 0 and 21. Taken together, all these observations confirm the positive effect of MY-FGF2
714 on cell proliferation, collagen fibril formation and ECM development for tendon regeneration.




715

716 **Figure 6.** The confocal microscopy observation of rTFs cultured in MY or MY-FGF2
 717 scaffolds up to 21 days after staining type I collagen (COL I) or tenascin C with FITC-tagged
 718 antibody (green) and cell nuclei with DAPI (blue) (bar = 75 μ m). The numbers shown are
 719 semi-quantitative analysis of green fluorescence area percentages within each image.

720 **3.3 In vitro studies: dynamic culture**


721 As MY-FGF2 provides the best cues for tenogenic differentiation of rTFs, the MY-
722 FGF2/rTFs was further dynamically cultured in vitro under cyclic tensile loading in a
723 bioreactor. A previous study used 3, 6 or 9% cyclic loading on rabbit Achilles tendons at 0.25
724 Hz for 8 h/day to identify the optimal loading condition that can mimic the in vivo strain
725 environments of tendons [47]. The results confirmed that a tendon without loading strain lost
726 its structural integrity; 3% of cyclic tensile loading led to moderate matrix deterioration and
727 elevated expression levels of MMP-1, 3, and 12; loading at 9% caused massive rupture of
728 collagen bundle. In contrast, 6% cyclic strain-loaded tendons displayed structural integrity
729 and cellular function and thereby declaring the importance of mechanical stimulation in
730 tendon regeneration. Considering this study, the cyclic loading in MY-FGF2 was proposed at
731 3 and 5% strain for dynamic culture, and static culture in the same bioreactor without
732 mechanical loading (0% strain) was used as a reference for comparison. After dynamic
733 culture, MY-FGF2/rTFs constructs were observed under SEM for cell adhesion and the
734 morphology of adhered cells. Surprisingly, the density and morphology of cells in MY-FGF2
735 under dynamic culture was totally different from those under static culture. Each single yarn
736 in MY-FGF2 scaffolds was covered up with a cell layer of rTFs, whose thickness increases
737 with increasing strain value (**Figure 7A**). The elongated orientation of rTFs under dynamic
738 culture is also visible from the SEM images. The observation of higher cell density was
739 supported from DNA content measurements, indicating proliferation rate of rTFs is positively
740 correlated with the value strain up to 5% (**Figure 7B**). For cell orientation, the cytoskeletal
741 staining found the actin filament deposition is oriented along the fiber axis under dynamic
742 culture, together with more stained nuclei (**Figure 7C**). The highest cellular density as well as
743 actin cytoskeleton expression at 5% strain underlines the importance of mechanical
744 stimulation during cell growth.



745


746 **Figure 7.** The cell morphology from SEM (A, bar = 100 µm), the cell proliferation from
 747 DNA contents (B), and the staining of actin filaments cytoskeleton (C, bar = 75 µm) after
 748 mechanical stimulation of MY-FGF2/rTFs by culture in a bioreactor for 7 days with 3 h
 749 stretching per day at 0.5 Hz frequency, and with 0, 3 or 5% strain. * $p < 0.05$, ** $p < 0.01$.

750 For gene expression under dynamic culture, mechanical stimulation promotes the
 751 expression of COL I and tenascin C gene, with the relative mRNA levels influenced by the
 752 strain value (**Figure 8**). The expression of COL I is in the order 0% < 3% < 5%, indicating
 753 mechanical stimulation promotes tenocyte maturation and synthesis of ECM [48]. Similar to
 754 COL I, the gene expression of tenascin C is also highly up-regulated from mechanical
 755 stimulation. A reverse trend was found for COL III and fibronectin. As stated before, COL III
 756 is an early gene expressed during the tendon regeneration process, where it will be converted
 757 into COL I as tendon matures [38]. Therefore, COL III expression is the highest at 0% strain
 758 and decreased with increasing cyclic stretching strain. The COL III gene expression
 759 drastically dropped at 5% stretching, implying mechanical stimulation can increase the tendon
 760 maturation rate. Fibronectin is an early expressing gene during the attachment and survival of
 761 the cells. During tendon repair, it will be expressed in large quantities throughout the growth
 762 period. The fibronectin gene expression of rTFs decreased significantly by cyclic tensile
 763 loading, which reveals the relevance of mechanical stimulation towards successful tendon
 764 regeneration [42]. Unlike gene expression patterns of other genes, biglycan exhibited similar
 765 mRNA levels irrespective of cyclic stretching stain at 0, 3 or 5%. The unchanged mRNA
 766 levels of biglycan thus confirms its gene expression was not affected by mechanical
 767 stimulation, as has been reported before [49].



768
 769 **Figure 8.** The gene expression analysis of type I collagen (COL I), tenascin C, type III
 770 collagen (COL III), fibronectin and biglycan from qRT-PCR after mechanical stimulation of
 771 MY-FGF2/rTFs by culture in a bioreactor for 7 days, with 3 h stretching per day at 0.5 Hz
 772 frequency, and with 0, 3 or 5% strain.

773 The effect of cyclic stretching on synthesis of key tendon marker proteins was
774 examined through qualitative assessment of time-lapsed COLI and tenascin C fluorescence
775 signal change during immunofluorescence (IF) staining. The deposition of both proteins is
776 found to be increased with increasing strain value, as well as the density DAPI-stained nuclei
777 (**Figure 9**). The oriented deposition of FITC-labelled proteins re-affirms the influence from
778 fiber orientation in the yarn bundles. Undoubtedly, the application of cyclic strain along the
779 fiber axis provides pronounced effect on protein production and distribution, presumably from
780 the directional mechanical stimulation during cell growth. The protein deposition therefore
781 reaches the maximum under the highest cyclic stretching (5% strain). The semi-quantitative
782 estimation of green fluorescence area in the confocal images is 48.7% for COL I and 34.2%
783 for tenascin C at 0% strain. This value increases to 87.6% (3% strain) and 97.9% (5% strain)
784 for COL I, and to 77% (3% strain) and 95.5% (5% strain) for tenascin C. These results are
785 consistent with the fact that mechanical stimulation can enhance maturation of rTFs to
786 enhance COL I and tenascin C production [50]. It is also consistent with the report that the
787 direction during mechanical stimulation and fiber orientation of the scaffold could induce
788 uniaxial cellular alignment by affecting cell morphology [51].



789


790 **Figure 9.** The immunofluorescence staining images of type I collagen (COL I) (A) and
 791 tenascin C (B). A MY-FGF2/rTFs construct was mechanically stimulated by culture in a
 792 bioreactor for 7 days, with 3 h stretching per day at 0.5 Hz frequency, and with 0, 3 or 5%
 793 strain. The protein was stained with FITC-tagged antibody (green) and cell nuclei were
 794 stained with DAPI (blue). The numbers shown are semi-quantitative analysis of green
 795 fluorescence area percentages within each image. Bar = 75 μ m.

796 **3.4 In vivo studies**

797 The ability of a dynamic-cultured MY-FGF2/rTFs implant towards extensor digitorum
798 tendon (EDT) regeneration was examined from the six-week harvested samples. During the
799 experiment, a defect was created for an EDT and a cell-free (acellular) or a cell-seeded
800 (cellular) MY-FGF2 scaffold was sutured to both ends of the created defect for repair (**Figure**
801 **10A**). The tendon disruption is clearly visible before implantation and the dimension of the
802 MY-FGF2 scaffold was well-controlled to be matching the diameter and length of an EDT.
803 Scaffolds were sutured to the terminals of each disruption end and the suturing was made
804 intact through enlacing inside the tied terminals of MY-FGF2 scaffolds. Six-week after
805 implantation, the scaffold appeared to be embedded in the native tendon through sutured
806 terminals and gross view of neo-tendon confirmed the successful bridging of implanted
807 scaffolds to the proximal and distal ends to initiate regeneration. There was no significant
808 difference between the acellular and the cellular groups in appearance, but it can be observed
809 that implant shape is not deformed 6 weeks from implantation. The mechanical stability of the
810 scaffolds has been tested through physical pulling, using forceps. From the physical
811 appearance it was confirmed that the suture-embedded yarn-based MY-FGF2 scaffold can be
812 considered an alternative for the current knot problems of commercial microfibers used for
813 tendon surgery [52].

814 To assess the tendon regeneration potential in vivo, H&E, Masson's trichrome and IHC
815 staining of tendon specific marker protein COL I, Col III and tenascin C was performed
816 (**Figure 10B**). Compared with acellular samples, the H&E staining of cellular samples
817 displayed highly organized tissue morphology. Abundant cells were found in the cellular
818 sample in contrast to sporadic infiltrated cells in the acellular sample, where hematoxylin
819 stains cell nuclei to purplish blue and eosin stains ECM and cytoplasm to pink, endorsing
820 successful tissue regeneration [53]. In case of acellular samples, the intermittent voids and
821 wavy appearance are due to the presence of fibrous environment without cellular
822 proliferation. In further, the distribution of collagen fibers was analyzed through Masson's
823 trichrome staining. As COL I is the most abundant component in the tendon tissue, the blue
824 color from Masson's trichrome staining can be used to compare the collagen distribution in a
825 neo-tendon tissue. The cellular scaffold obviously has a directional deposition of collagen
826 fibers in dark blue, which is detected at negligible level in the acellular sample. The fiber-like
827 parallel deposition confirms the initiation of collagen bundle formation in the implanted
828 cellular construct. The appearance of minimum level of blue stain from the acellular sample

829 must be due to the migration of tendon cells from the proximal and distal ends of disrupted
 830 native tendons in rabbits.



831
 832 **Figure 10.** (A) The extensor digitorum tendon (EDT) defect was repaired with a MY-FGF2
 833 scaffold (acellular) or a MY-FGF2/rTFs construct after 7-day in vitro cell culture at 5% strain
 834 (cellular), by suturing to distal and proximal ends of native tendon. The grafts were explanted
 835 6-week after implantation. (B) The H&E stain, Masson's trichrome stain,
 836 immunohistochemical (IHC) analyses of tendon specific markers type I collagen (COL I), type
 837 III collagen (COL III) and tenascin C (bar = 10 μ m). (C) The typical force-displacement

838 curves of native tendon, and cellular and acellular samples retrieved 6 weeks post-implantation,
839 by tensile mechanical testing.
840

841 The IHC staining was further performed to identify the synthesis of tendon-specific
842 proteins secreted by transplanted rTFs in the scaffold. As COL I is an important protein in the
843 remodeling phase of the tendon, secreted by mature cells, it is more rational to examine the
844 presence of COL I in the regenerating material to validate tendon growth. The dark brown
845 deposition observed from COL I staining in the cellular sample indicates abundant presence
846 of COL I, where acellular sample reveals only a light staining intensity (**Figure 10B**). Similar
847 to the aligned deposition in observed from Masson's trichrome staining, COL I in cellular
848 sample follows similar pattern and thus supports tendon regeneration. The dark brownish
849 nodules appears in the cellular sample is due to the deposition of secreted COL I around cell
850 surface, which can be verified from the nuclear staining nodules from H&E stain. As tenascin
851 C is produced during the proliferation and re-construction phases during tendon healing, its
852 secretion will be minimum at early stages and increase with time. That the staining intensity
853 of tenascin C for the cellular sample is significantly higher than the acellular sample thus
854 supports continuous tenogenic differentiation of rTFs in vivo. This can be correlated with the
855 protein synthesis and gene expression levels observed in vitro. Both COL I and tenascin C
856 deposit along the direction of bundle axis and thus entertain the elongated morphology of
857 native tendons. COL III was verified further to analyze tendon formation, which is composed
858 of shorter fibers and observed at the growth phase of tendon re-construction/regeneration.
859 Being an early expressing protein, the secretion COL III will decrease with the maturation of
860 cells and the growth of collagen fibers, and thus accounts for the light staining intensity
861 observed (**Figure 10B**). Moreover, there was no significant difference is staining intensity
862 between the cellular and acellular samples, and thus accounts for a mature neo-tendon tissue
863 formed by the implanted MY-FGF2/rTFs construct. The down-regulated COL III staining
864 intensity at 6-week implantation period compared with COL I points out the characteristic of
865 enhanced tendon regeneration provided by MY-FGF2 after mechanical stimulation. Overall,
866 the mechanically stimulated MY-FGF2 scaffolds pre-cultured with rTFs could be deemed as
867 an ideal tissue engineering construct for tendon repair or replacement.

868 At the end of in vivo experiments, repaired tendons from the acellular and cellular
869 groups were explanted and subject to biomechanical analysis using tensile testing. A native
870 EDT was also retrieved and subject to the same test for comparison. As shown from the force
871 (load) (N)-displacement (elongation) (mm) curves, both samples show characteristic tendon

872 mechanical behavior under tensile testing from the force-displacement curve, with an initial
 873 toe-region followed by a linear region till failure (**Figure 10C**). The mean value of stiffness,
 874 calculated from the slope of the linear region in the force-displacement curve for the cellular
 875 sample is 7.48 N/mm, which is similar to that of the acellular sample (6.98 N/mm) (**Table 2**).
 876 However, the maximum load and the maximum displacement at failure increase significantly
 877 from the acellular to the cellular sample. The mean values of maximum force increases from
 878 6.22 N to 16.58 N, and the maximum displacement from 1.23 mm to 3.50 mm. This also
 879 results in 3.5-fold increase of stored energy for the cellular sample. Compared with a native
 880 tendon, only the cellular sample, but not the acellular one, shows similar stiffness, maximum
 881 displacement and maximum load force with no significant difference. Nonetheless, the stored
 882 energy of the cellular sample is still significantly less than that of a native tendon,
 883 representing only 45% of its mean value. This may arise from limited sample size and
 884 insufficient implantation time during in vivo studies. Although retrieved MY-FGF2 is with
 885 similar stiffness, only rTFs-seeded MY-FGF2 construct can generate a tendon structure with
 886 similar force and displacement with a native tendon tissue, presumably from production of
 887 tendon-specific proteins in the ECM of neo-tendon, as shown from the IHC images.

888

889 **Table 2.** The tensile mechanical properties of native tendons, and cellular and acellular
 890 samples retrieved 6 weeks post-implantation in a rabbit extensor digitorum tendon defect
 891 model (n = 3).

	Native	Cellular	Acellular
Maximum load (N)	20.26 ± 3.74	16.58 ± 3.05	6.22 ± 3.15 ^{α,β}
Maximum displacement (mm)	4.00 ± 1.13	3.50 ± 0.45	1.23 ± 0.84 ^{α,β}
Stiffness (N/mm)	7.20 ± 0.28	7.48 ± 1.18	6.98 ± 2.18
Energy (mJ)	32.93 ± 6.13	15.03 ± 5.10 ^α	4.24 ± 5.12 ^{α,β}

892 ^α*p* < 0.05 compared with native, ^β*p* < 0.05 compared with cellular.

893

894 4. Conclusion

895 A suture-reinforced single yarn (SY) of PCL aligned fibers was prepared by collecting
 896 PCL fibrous structure with an extending commercial surgical suture. Three SY were
 897 successfully braided together to fabricate a multiple yarn (MY) scaffold with high flexibility,
 898 mechanical strength and fibrous surface topography. The fibers in the fibrous sheath can align
 899 in a twisting angle on top of the suture, which can be further surface grafted with heparin for

900 FGF2 binding to enable faster tendon regeneration. From spectroscopy and microscopy
901 analysis, serial surface modification and surface grafting did not affect the yarn morphology.
902 Thermogravimetric analysis and probing with FGF2-antibody confirm the presence of heparin
903 and FGF2 in the scaffold. In vitro studies with rTFs displayed higher cell proliferation in MY-
904 FGF2 scaffold with high cell viability from Live/Dead staining and cell adhesion and
905 proliferation in alignment with fiber orientation is observed from cytoskeletal staining. Up-
906 regulated gene expression of tenogenic marker genes validates effective tendon regeneration
907 using MY-FGF2 where enhanced synthesis of tenogenic marker proteins is also evident from
908 immunofluorescence staining. When in vitro characterizations in static culture were compared
909 with dynamic culture with 3% and 5% strain, MY-FGF2/rTFs mechanically stimulated at 5%
910 strain displayed optimum cell proliferation rate, cytoskeletal expression, gene expression and
911 protein synthesis. The regeneration efficiency of the optimized constructed fabricated in vitro
912 was used for repair of tendon defect in rabbits with dissected EDT. The histological analysis
913 and biomechanical analysis of the explanted samples six weeks after implantation not only
914 reveal the regeneration capability of MY-FGF2/rTFs but also demonstrate its mechanical
915 suitability to compete with an autologous tendon grafts. As of today, the commonly used non-
916 degradable microfibrinous scaffolds were lacking the ability to maintain a cell-friendly
917 environment for tendon regeneration. In contrast, when fibrous scaffolds were proposed, none
918 of them were capable to meet the extreme mechanical stability and flexibility demanded. In
919 this context, the novel scaffold design proposed here is expected to have an impact on
920 development of tendon grafts for clinical use.

921

922 **Acknowledgements**

923 We are thankful for financial supports from Chang Gung Memorial Hospital, Taiwan
924 (CMRPD2J0111, CMRPD2J0112 and CMRPD2J0113) and the Ministry of Science and
925 Technology, Taiwan (MOST 109-2314-B-182-013-MY3). K.T. Shalumon acknowledges the
926 financial aid from the Ramalingaswami Fellowship, Department of Biotechnology, India. The
927 technical support by the Microscopy Center, Chang Gung University and the Microscope
928 Core Laboratory, Chang Gung Memorial Hospital, Linkou are acknowledged.

929

930 **References**

931 [1] M. Kjaer, Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical
932 loading, *Physiological reviews* 84 (2004) 649-698.

933 [2] C.T. Thorpe, H.R. Screen, Tendon Structure and Composition, *Adv. Exp. Med. Biol.* 920 (2016) 3-
934 10.

935 [3] P.K. Nguyen, K. Baek, F. Deng, J.D. Criscione, R.S. Tuan, C.K. Kuo, 2.6.5 - Tendon Tissue-
936 Engineering Scaffolds, in: W.R. Wagner, S.E. Sakiyama-Elbert, G. Zhang, M.J. Yaszemski (Eds.)
937 *Biomaterials Science (Fourth Edition)*, Academic Press 2020, pp. 1351-1371.

938 [4] A. Sensini, G. Massafra, C. Gotti, A. Zucchelli, L. Cristofolini, Tissue Engineering for the Insertions
939 of Tendons and Ligaments: An Overview of Electrospun Biomaterials and Structures, *Frontiers in*
940 *Bioengineering and Biotechnology* 9 (2021).

941 [5] S. Ruiz-Alonso, M. Lafuente-Merchan, J. Ciriza, L. Saenz-del-Burgo, J.L. Pedraz, Tendon tissue
942 engineering: Cells, growth factors, scaffolds and production techniques, *J. Control. Release* 333
943 (2021) 448-486.

944 [6] D.L. Butler, C. Gooch, K.R.C. Kinneberg, G.P. Boivin, M.T. Galloway, V.S. Nirmalanandhan, J.T.
945 Shearn, N.A. Dymont, N. Juncosa-Melvin, The use of mesenchymal stem cells in collagen-based
946 scaffolds for tissue-engineered repair of tendons, *Nature Protocols* 5 (2010) 849-863.

947 [7] S. Saber, A.Y. Zhang, S.H. Ki, D.P. Lindsey, R.L. Smith, J. Riboh, H. Pham, J. Chang, Flexor Tendon
948 Tissue Engineering: Bioreactor Cyclic Strain Increases Construct Strength, *Tissue Engineering Part A*
949 16 (2010) 2085-2090.

950 [8] Z. Mao, B. Fan, X. Wang, X. Huang, J. Guan, Z. Sun, B. Xu, M. Yang, Z. Chen, D. Jiang, J. Yu, A
951 Systematic Review of Tissue Engineering Scaffold in Tendon Bone Healing in vivo, *Frontiers in*
952 *Bioengineering and Biotechnology* 9 (2021).

953 [9] J. Cai, X. Xie, D. Li, L.-R. Wang, J. Jiang, X.-m. Mo, J. Zhao, A novel knitted scaffold made of
954 microfiber/nanofiber core-sheath yarns for tendon tissue engineering, *Biomaterials science* 8 (2020).

955 [10] Z. Zheng, J. Ran, W. Chen, Y. Hu, T. Zhu, X. Chen, Z. Yin, B.C. Heng, G. Feng, H. Le, C. Tang, J.
956 Huang, Y. Chen, Y. Zhou, P. Dominique, W. Shen, H.-w. Ouyang, Alignment of collagen fiber in knitted
957 silk scaffold for functional massive rotator cuff repair, *Acta biomaterialia* 51 (2017) 317-329.

958 [11] W. Zhang, Y. Yang, K. Zhang, Y. Li, G. Fang, Weft-knitted silk-poly(lactide-co-glycolide) mesh
959 scaffold combined with collagen matrix and seeded with mesenchymal stem cells for rabbit Achilles
960 tendon repair, *Connective tissue research* 56 (2015) 25-34.

961 [12] S. Wu, Y. Wang, P.N. Streubel, B. Duan, Living nanofiber yarn-based woven biotextiles for tendon
962 tissue engineering using cell tri-culture and mechanical stimulation, *Acta biomaterialia* 62 (2017) 102-
963 115.

964 [13] O. Hakimi, P.A. Mouthuy, N. Zargar, E. Lostis, M. Morrey, A. Carr, A layered electrospun and
965 woven surgical scaffold to enhance endogenous tendon repair, *Acta biomaterialia* 26 (2015) 124-135.

966 [14] S. Wu, B. Duan, P. Liu, C. Zhang, X. Qin, J.T. Butcher, Fabrication of Aligned Nanofiber Polymer
967 Yarn Networks for Anisotropic Soft Tissue Scaffolds, *ACS Applied Materials & Interfaces* 8 (2016)
968 16950-16960.

969 [15] S. Omeroglu, The effect of braiding parameters on the mechanical properties of braided ropes,
970 *Fibres and Textiles in Eastern Europe* 14 (2006) 53-57.

971 [16] T.D.M.D. Rosenberg, Knee Ligaments. Structure, Function, Injury, and Repair, *JBSJ* 73 (1991) 477.

972 [17] B.A. Smith, G.A. Livesay, S.L. Woo, Biology and biomechanics of the anterior cruciate ligament,
973 *Clinics in sports medicine* 12 (1993) 637-670.

974 [18] W.-J. Li, Y. Jiang, R. Tuan, Chondrocyte Phenotype in Engineered Fibrous Matrix Is Regulated by
975 Fiber Size, *Tissue engineering* (2006) 060802052515028.

976 [19] D.M. Kalaskar, F. Alshomer, Chapter 8 - Micro- and Nanotopographical Cues Guiding Biomaterial
977 Host Response, in: S.J. Lee, J.J. Yoo, A. Atala (Eds.) *In Situ Tissue Regeneration*, Academic Press,
978 Boston, 2016, pp. 137-163.

979 [20] C. Lee, H. Shin, I. Cho, Y.-M. Kang, I. Kim, K. Park, J.-w. Shin, Nanofiber alignment and direction of
980 mechanical strain affect the ECM production of human ACL fibroblast, *Biomaterials* 26 (2005) 1261-
981 1270.

982 [21] K. Spanoudes, D. Gaspar, A. Pandit, D.I. Zeugolis, The biophysical, biochemical, and biological
983 toolbox for tenogenic phenotype maintenance in vitro, *Trends Biotechnol.* 32 (2014) 474-482.

984 [22] M. Hogan, K. Girish, R. James, G. Balian, S. Hurwitz, A.B. Chhabra, Growth differentiation factor-5
985 regulation of extracellular matrix gene expression in murine tendon fibroblasts, *Journal of Tissue*
986 *Engineering and Regenerative Medicine* 5 (2011) 191-200.

987 [23] J.-P. Chen, W.-L. Lee, Collagen-grafted temperature-responsive nonwoven fabric for wound
988 dressing, *Appl. Surf. Sci.* 255 (2008) 412-415.

989 [24] J. Zhang, J.H. Wang, Characterization of differential properties of rabbit tendon stem cells and
990 tenocytes, *BMC musculoskeletal disorders* 11 (2010) 10.

991 [25] X. Zhang, W. Chang, P. Lee, Y. Wang, M. Yang, J. Li, S.G. Kumbar, X. Yu, Polymer-Ceramic Spiral
992 Structured Scaffolds for Bone Tissue Engineering: Effect of Hydroxyapatite Composition on Human
993 Fetal Osteoblasts, *PloS one* 9 (2014) e85871.

994 [26] Y.J. Kim, R.L. Sah, J.Y. Doong, A.J. Grodzinsky, Fluorometric assay of DNA in cartilage explants
995 using Hoechst 33258, *Analytical biochemistry* 174 (1988) 168-176.

996 [27] J.P. Chen, M.J. Tsai, H.T. Liao, Incorporation of biphasic calcium phosphate microparticles in
997 injectable thermoresponsive hydrogel modulates bone cell proliferation and differentiation, *Colloids*
998 *and surfaces. B, Biointerfaces* 110 (2013) 120-129.

999 [28] C.H. Chen, D.L. Li, A.D. Chuang, B.S. Dash, J.P. Chen, Tension Stimulation of Tenocytes in Aligned
1000 Hyaluronic Acid/Platelet-Rich Plasma-Polycaprolactone Core-Sheath Nanofiber Membrane Scaffold
1001 for Tendon Tissue Engineering, *Int. J. Mol. Sci.* 22 (2021).

1002 [29] W.-E. Teo, R. Gopal, R. Ramaseshan, K. Fujihara, S. Ramakrishna, A dynamic liquid support
1003 system for continuous electrospun yarn fabrication, *Polymer* 48 (2007) 3400-3405.

1004 [30] U. Ali, Y. Zhou, X. Wang, T. Lin, Direct electrospinning of highly twisted, continuous nanofiber
1005 yarns, *The Journal of The Textile Institute* 103 (2012) 80-88.

1006 [31] I.-K. Kang, O.H. Kwon, Y.M. Lee, Y.K. Sung, Preparation and surface characterization of functional
1007 group-grafted and heparin-immobilized polyurethanes by plasma glow discharge, *Biomaterials* 17
1008 (1996) 841-847.

1009 [32] S.-H. Chen, C.-H. Chen, K. Shalumon, J.-P. Chen, Preparation and characterization of antiadhesion
1010 barrier film from hyaluronic acid-grafted electrospun poly(caprolactone) nanofibrous membranes for
1011 prevention of flexor tendon postoperative peritendinous adhesion, *International journal of*
1012 *nanomedicine* 9 (2014) 4079-4092.

1013 [33] O.A. Ibrahim, F. Zhang, S.C. Lang Hrstka, M. Mohammadi, R.J. Linhardt, Kinetic model for FGF,
1014 FGFR, and proteoglycan signal transduction complex assembly, *Biochemistry* 43 (2004) 4724-4730.

1015 [34] N.L. Leong, A. Arshi, N. Kabir, A. Nazemi, F.A. Petrigliano, B.M. Wu, D.R. McAllister, In vitro and in
1016 vivo evaluation of heparin mediated growth factor release from tissue-engineered constructs for
1017 anterior cruciate ligament reconstruction, *J. Orthop. Res.* 33 (2015) 229-236.

1018 [35] L. Nieto, Á. Canales, I.S. Fernández, E. Santillana, R. González-Corrochano, M. Redondo-Horcajo,
1019 F.J. Cañada, P. Nieto, M. Martín-Lomas, G. Giménez-Gallego, J. Jiménez-Barbero, Heparin Modulates
1020 the Mitogenic Activity of Fibroblast Growth Factor by Inducing Dimerization of its Receptor. A 3D
1021 View by Using NMR, *Chembiochem* 14 (2013) 1732-1744.

1022 [36] J. Bojsen-Møller, S.P. Magnusson, Mechanical properties, physiological behavior, and function of
1023 aponeurosis and tendon, *Journal of Applied Physiology* 126 (2019) 1800-1807.

1024 [37] B.P. Chan, K.M. Chan, N. Maffulli, S. Webb, K.K. Lee, Effect of basic fibroblast growth factor. An
1025 in vitro study of tendon healing, *Clinical orthopaedics and related research* (1997) 239-247.

1026 [38] I.R. Sigal, D.A. Grande, D.M. Dines, J. Dines, M. Drakos, Biologic and Tissue Engineering Strategies
1027 for Tendon Repair, *Regenerative Engineering and Translational Medicine* 2 (2016) 107-125.

1028 [39] C.H. Jo, H.J. Lim, K.S. Yoon, Characterization of Tendon-Specific Markers in Various Human
1029 Tissues, Tenocytes and Mesenchymal Stem Cells, *Tissue engineering and regenerative medicine* 16
1030 (2019) 151-159.

1031 [40] W. Wang, J. He, B. Feng, Z. Zhang, W. Zhang, G. Zhou, Y. Cao, W. Fu, W. Liu, Aligned nanofibers
1032 direct human dermal fibroblasts to tenogenic phenotype in vitro and enhance tendon regeneration
1033 in vivo, *Nanomedicine (London, England)* 11 (2016) 1055-1072.

1034 [41] J. Lu, L. Jiang, Y. Chen, K. Lyu, B. Zhu, Y. Li, X. Liu, X. Liu, L. Long, X. Wang, H. Xu, D. Wang, S. Li,
1035 The Functions and Mechanisms of Basic Fibroblast Growth Factor in Tendon Repair, *Front. Physiol.* 13
1036 (2022) 852795.

1037 [42] S. Sahoo, S.L. Toh, J.C. Goh, A bFGF-releasing silk/PLGA-based biohybrid scaffold for
1038 ligament/tendon tissue engineering using mesenchymal progenitor cells, *Biomaterials* 31 (2010)
1039 2990-2998.

1040 [43] J.R. Venugopal, S. Zhang Y Fau - Ramakrishna, S. Ramakrishna, In vitro culture of human dermal
1041 fibroblasts on electrospun polycaprolactone collagen nanofibrous membrane.

1042 [44] R.A. Bagchi, J. Lin, R. Wang, M.P. Czubryt, Regulation of fibronectin gene expression in cardiac
1043 fibroblasts by scleraxis, *Cell Tissue Res* 366 (2016) 381-391.

1044 [45] L.M. Dourte, L. Pathmanathan, M.J. Mienaltowski, A.F. Jawad, D.E. Birk, L.J. Soslowsky,
1045 Mechanical, compositional, and structural properties of the mouse patellar tendon with changes in
1046 biglycan gene expression, *J. Orthop. Res.* 31 (2013) 1430-1437.

1047 [46] K.T. Shalumon, H.-T. Liao, C.-Y. Kuo, C.-B. Wong, C.-J. Li, M. P.A, J.-P. Chen, Rational design of
1048 gelatin/nanohydroxyapatite cryogel scaffolds for bone regeneration by introducing chemical and
1049 physical cues to enhance osteogenesis of bone marrow mesenchymal stem cells, *Materials Science*
1050 *and Engineering: C* 104 (2019) 109855.

1051 [47] T. Wang, Z. Lin, R.E. Day, B. Gardiner, E. Landao-Bassonga, J. Rubenson, T.B. Kirk, D.W. Smith,
1052 D.G. Lloyd, G. Hardisty, A. Wang, Q. Zheng, M.H. Zheng, Programmable mechanical stimulation
1053 influences tendon homeostasis in a bioreactor system, *Biotechnology and bioengineering* 110 (2013)
1054 1495-1507.

1055 [48] N. Sawaguchi, T. Majima, T. Funakoshi, K. Shimode, K. Harada, A. Minami, S.-I. Nishimura, Effect
1056 of cyclic three-dimensional strain on cell proliferation and collagen synthesis of fibroblast-seeded
1057 chitosan-hyaluronan hybrid polymer fiber, *Journal of Orthopaedic Science* 15 (2010) 569-577.

1058 [49] C. Popov, M. Burggraf, L. Kreja, A. Ignatius, M. Schieker, D. Docheva, Mechanical stimulation of
1059 human tendon stem/progenitor cells results in upregulation of matrix proteins, integrins and MMPs,
1060 and activation of p38 and ERK1/2 kinases, *BMC Mol. Biol.* 16 (2015) 6.

1061 [50] Y. Xu, S. Dong, Q. Zhou, X. Mo, L. Song, T. Hou, J. Wu, S. Li, Y. Li, P. Li, Y. Gan, J. Xu, The effect of
1062 mechanical stimulation on the maturation of TDSCs-poly(L-lactide-co-e-caprolactone)/collagen
1063 scaffold constructs for tendon tissue engineering, *Biomaterials* 35 (2014) 2760-2772.

1064 [51] Savio L.-Y. Woo, Richard E. Debski, Jennifer Zeminski, Steven D. Abramowitch, M. Serena S. Chan
1065 Saw, and, J.A. Fenwick, Injury and Repair of Ligaments and Tendons, *Annual review of biomedical*
1066 *engineering* 2 (2000) 83-118.

1067 [52] S. Rawson, S. Cartmell, J. Wong, Suture techniques for tendon repair; a comparative review,
1068 *Muscles, ligaments and tendons journal* 3 (2013) 220-228.

1069 [53] D.W. Youngstrom, J.G. Barrett, R.R. Jose, D.L. Kaplan, Functional characterization of detergent-
1070 decellularized equine tendon extracellular matrix for tissue engineering applications, *PLoS One* 8
1071 (2013) e64151.



Click here to access/download
Supplementary Material
Supplimentary materials-v1.pdf



Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Jyh-Ping Chen reports financial support was provided by Chang Gung Memorial Hospital Linkou. Jyh-Ping Chen reports financial support was provided by Ministry of Science and Technology.